Drug – bio-affecting and body treating compositions – Solid synthetic organic polymer as designated organic active... – Monomer contains oxygen
Reexamination Certificate
2002-04-24
2010-11-23
Fubara, Blessing M (Department: 1618)
Drug, bio-affecting and body treating compositions
Solid synthetic organic polymer as designated organic active...
Monomer contains oxygen
C424S078080
Reexamination Certificate
active
07837987
ABSTRACT:
To achieve, an in vivo repair of injured mammalian nerve tissue, an effective amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be preformed by directly contacting the agent with the nerve tissue at the site of the injury. Alternatively, the biomembrane fusion agent is delivered to the site of the injury through the blood supply after administration of the biomembrane fusion agent to the patient. The administration is preferably by parenteral administration including intravascular, intramuscular, subcutaneous, or intraperitoneal injection of an effective quantity of the biomembrane fusion agent so that an effective amount is delivered to the site of the nerve tissue injury.
REFERENCES:
patent: 4369769 (1983-01-01), Edwards
patent: 4599354 (1986-07-01), Shulman
patent: 4919140 (1990-04-01), Borgens et al.
patent: 5382584 (1995-01-01), Balasubramanian
patent: 5470568 (1995-11-01), Lee
patent: 5523492 (1996-06-01), Emanuele et al.
patent: 5545648 (1996-08-01), Hansebout et al.
patent: 5605687 (1997-02-01), Lee
patent: 5641637 (1997-06-01), Hudak et al.
patent: 6090823 (2000-07-01), Ishikawa
patent: 6093509 (2000-07-01), Isono et al.
patent: 6232297 (2001-05-01), Linden et al.
patent: 6432434 (2002-08-01), Meyerhoff et al.
patent: 6440455 (2002-08-01), Berowitz
patent: 6495532 (2002-12-01), Bathurst et al.
patent: 2004/0214790 (2004-10-01), Borgens
patent: 2005/0069520 (2005-03-01), Shi et al.
patent: 0 484 186 (1992-05-01), None
patent: 0 484 186 (1999-12-01), None
patent: WO97/35577 (1997-10-01), None
patent: WO98/41213 (1998-09-01), None
patent: WO 02/092107 (2002-11-01), None
patent: WO2004/060146 (2004-07-01), None
Borgens et al. (“Immediate recovery form spinal cord injury through molecular repair of nerve membranes with polyethylene glycol” in FASEB, vol. 14, 27-35, Jan. 2000).
Benzon et al. “The Effect of Polyethylene Glycol on Mammalian Nerve Impulses”Anesth. Analg. 1987;66:553-9.
Borgens, Richard B. Electrically Mediated Trauma Repair. Grant No. DAMD17-94-J-4242. Final Report. NTIS Item No. ADA 359272. Sep. 1998. 139 pages.
Borgens et al. “A subcutaneous tri-block copolymer produces recovery from spinal cord injury”J. Neurosci. Res. 2004;76:141-154.
Callahan “Help for paralyzed dogs”Star TribuneDec. 4, 2004, p. A5.
Carpenter et al. “Response of dogs to repeated intravenous injection of polyethylene glycol 4000 with notes on excretion and sensitization.”Toxicol. Appl. Pharmacol. 1971;18:35-40.
Hansen et al. “A pathological-anatomical study on disk degeneration in dog with special reference to the so-called enchondrosis intervertebralis”Acta Orth Scand1952;11:1-129.
Horelein, B.F. “Comparative disk disease: man and dog.”JAAHA1979;15:535-545.
Laverty et al. “A Preliminary Study of Intravenous Surfactants in Paraplegic Dogs: Polymer Therapy in Canine Clinical SCI”J. of Neurotrauma2004;21:1767-1777.
Luo et al. “Polyethylene glycol immediately repairs neuronal membranes and inhibits free radical production after acute spinal cord injury”J. Neurochemistry2002;83:471-480.
Maskarinec et al. “Direct observation of poloxamer 188 insertion into lipid monolayers”Biophys. J. 2002;82:1453-1459.
McNally et al. “Three-Dimensional Imaging of Living and Dying Neurons with Atomic Force Microscopy”J. Neurocytology2004;33:251-258.
Pointillart et al. “Pharmacological therapy of spinal cord injury during the acute phase”Spinal Cord2000;38:71-76.
Principe, A.H. “Polyethylene glycols. Studies of absorption, excretion, retention, and identification”J. Forensic Sci. 1968;13:90-113.
Selby, R.Neurosurgery“Correspondence” 1983;12:5:591.
Shaffer et al. “The absorption and excretion of the solid polyethylene glycols” (“Carbowax” Compounds).J. Amer. Pharm. Assoc. 1947;36:152-157.
Shaffer et al. “Renal excretion and volume distribution of some polyethylene glycols in the dog.”Amer. J. Of Phys. 1948;152:93-99.
Short et al. “High dose methylprednisolone is the management of acute spinal cord injury—a systematic review from a clinical perspective”Spinal Cord2000;38:273-286.
Smyth et al. “The toxicity of high molecular weight polyethylene glycols; chronic oral and parenteral administration.”J. Amer. Pharm. Assoc. 1947;36:157-160.
Working et al. Safety of poly (ethylene glycol) and poly (ethylene glycol) derivatives in Poly (ethylene glycol) chemistry and biological applications. Harris and Zalipsky (eds.), inPolyethylene glycol):Chemistry and Biological Applications1997;Title page, Table of Contents, and pp. 45-57.
Adams-Graves et al., “RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study,”Blood, Sep. 1, 1997; 90(5):2041-6.
Ahkong et al., “Movements of fluorescent probes in the mechanism of cell fusion induced by poly(ethylene glycol),”J. Cell Sci., 1987; 88:389-98.
Aldewinckel et al., “Effects of Poly (Ethylene Glycol) on Liposomes and Erythrocytes permeability changes and membrane fusion,”Biochim. Biophys. Acta., 1982; 689:548-560.
Allen, “Surgery of experimental lesion of spinal cord equivalent to crush injury of fracture dislocation of spinal column,”J. Am. Med. Assoc., Sep. 9, 1911; 57:878-880.
Anderson et al., “Characteristics of intraspinal grafts and locomotor function after spinal cord injury,”Proceedings of the Third Altschul Symposium on Neural Cell Specification: Molecular Mechanisms and Neurotherapeutic Implications, Juurlink et al., eds., Plenum Press, New York, 1995; 249-266.
Anderson et al., “Regeneration of spinal neurons in inframammalian vetebrates: morphological and developmental aspects,”J. Hirnforsch., 1983; 24:371-398.
Armstrong et al., “Inhibition of red blood cell-inducted platelet aggregation in whole blood by a nonionic surfactant, poloxamer 188 (RheothRx® injection),”Thrombosis Research, 1995; 79(5/6):437-50.
Asano et al., “Horseradish peroxidase used to examine the distribution of axonal damage in spinal cord compression injury in vitro,”J. Neurotrauma, 1995; 12:993 (Abst. No. TS2).
Basso et al., “A Sensitive and reliable locomotor rating scale for open field testing in rats,”J. Neurotrauma, 1995; 12(1):1-21.
Benzel,Spine Surgery: Techniques, Complication Avoidance and Management, Philadelphia, PA 1999; cover page, title pages, table of contents and 369-387 and 389-400.
Berne et al. eds., “Generation and Conduction of Action Potentials,”Physiology, 3rdEdition, Mosby, St. Louis, MO, 1993; 36-54.
Bernstein et al., “Spinal cord regeneration: synaptic renewal and neurochemistry,”Neuronal Plasticity, Cotman, ed., Raven Press, New York, 1978; 49-71.
Bernstein et al., “Synaptic frequency alteration on rat ventral horn neurons in the first segment proximal to spinal cord hemisection: an ultrastructural statistical study of regenerative capacity,”J. Neurocytol., 1977; 6:85-102.
Bernstein et al., “Synaptic reorganization following regeneration of goldfish spinal cord,”Exp. Neurol., 1973; 41:402-410.
Berry, “Chapter 4: Regeneration in the central nervous system,”Recent Advances in Neuropathology, Smith et al., eds., Churchill Livingstone, New York, 1979; 67-111.
Bisby, “Regeneration of peripheral nervous system axons,”The Axon Book, Waxman et al., eds., Oxford UP, New York, 1995, 553-578.
Bittner, “Long-term survival of anucleate axons and its implications for nerve regeneration,”TINS, 1991; 14(5):188-193.
Bittner et al., “Reconnection of severed nerve axons with polyethylene glycol,”Brain Research, 1986; 367:351-355.
Blight et al., “Cutaneus trunci muscle reflex of the guinea pig,”J. Comp. Neurol., 1990; 296:614-633.
Blight, “Delay
Borgens Richard B.
Shi Riyi
Fubara Blessing M
Mueting Raasch & Gebhardt, P.A.
Purdue Research Foundation
LandOfFree
Methods and compositions for treating mammalian nerve tissue... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating mammalian nerve tissue..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating mammalian nerve tissue... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4203814